ObsEva Deal History & Licensing Activity
ObsEva is a biotech headquartered in Switzerland. Over the past three years, ObsEva has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
3
Top Modality
Small Molecules
Focus Area
Women's Health
ObsEva Recent Deal Activity
Licensing, acquisition, and partnership transactions involving ObsEva in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| linzagolix | Kissei Pharmaceutical | Small Molecules | Phase 3 | license | Apr 2026 |
ObsEva Pipeline Focus
Therapeutic areas and modalities where ObsEva is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
ObsEva Strategic Signals
Key indicators of ObsEva's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches ObsEva's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Women's Health assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
GnrhAntagonist Benchmarks
Upfront, milestone, and royalty benchmarks for gnrhantagonist deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About ObsEva Licensing & Deal Activity
ObsEva is a biotech company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, ObsEva ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for ObsEva include Women's Health (3 deals and trials). In terms of modality, ObsEva has shown particular interest in small molecules, gnrhantagonist.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for ObsEva and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against ObsEva's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.